Modulation of GABAA Receptors in the Treatment of Epilepsy
Eleonora Palma1,2, Gabriele Ruffolo1, Pierangelo Cifelli3
1Department of Physiology and Pharmacology, Istituto Pasteur-Fondazione Cenci Bolognetti, University of Rome Sapienza, Rome, Italy.
Background:
A variety of evidence suggested that an imbalance in excitatory and inhibitory neurotransmission could be one of the pathophysiological mechanisms underlying the occurrence and progression of seizures. Understanding the causes of this imbalance may provide essential insight into the basic mechanisms of epilepsy and may uncover novel targets for future drug therapies. Accordingly, GABA is the most important inhibitory neurotransmitter in the CNS and its receptors (e.g., GABAARs) can still be relevant targets of new antiepileptic drugs (AEDs).
Methods:
Up to now, a variety of modulating agents that directly or indirectly act at GABAARs have been proposed for restoring the physiological balance of excitation and inhibition in the epileptogenic brain. While benzodiazepine, barbiturates and allosteric modulators of GABAARs are well-known for their anticonvulsant effect, new compounds as modulators of chloride homeostasis or phytocannabinoids are not completely unraveled and their antiepileptic action is still matter of debate. In addition, several inflammatory mediators as cytokines and chemokines play an important role in the modulation of GABAAR function, even if further research is needed to translate these new findings from the bench to the bedside. Finally yet importantly, a new frontier in epilepsy research is represented by the observation that specific small noncoding RNAs, namely miRNAs, may regulate GABAAR function paving the road to therapeutic approaches based on the modulation of gene expression.
Conclusion:
Here, we review key physiological, neuropathological and functional studies that altogether strengthen the role of modulation of GABAARs function as therapeutic target. The discovery of the novel molecular mechanisms underlying the GABAergic transmission in epilepsy represents another heavy piece in the "epileptic puzzle". Even if GABAAR is an old story in the pharmacology of the epilepsy, the reviewed findings suggest that new players in the scenario need to be considered.
More Related Videos
08:04Identification and Classification of Position-specific GABAA Receptor Subunit Missense Variants for Their Role In Hippocampal Pyramidal Neurons
Published on: June 6, 2025
07:16Methods for the Discovery of Novel Compounds Modulating a Gamma-Aminobutyric Acid Receptor Type A Neurotransmission
Published on: August 16, 2018
Related Concept Videos
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Calcium Channel Blockers
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
Ligand-Gated Ion Channel Receptor: Gating Mechanism
